Baicalin Alleviates Chronic Pancreatitis Fibrosis and Islet Dysfunction via Targeting IFNAR ‐Mediated JAK / STAT Signaling and Immune Modulation
The FASEB Journal · 2025
DOI: 10.1096/fj.202501649r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Hehe Dou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Emergency Surgery Department, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China. Hauptthemen laut MEDLINE: Flavonoids, Pancreatitis, Chronic, Signal Transduction, STAT Transcription Factors. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Key Natural Science Research Project of Anhui Provincial Department of Education, General Program of Natural Science Foundation of Bengbu Medical University, Scientific Research Project of Bengbu Medical College.
Abstract (Originalsprache)
Chronic pancreatitis (CP) is characterized by progressive fibrosis and islet dysfunction, yet effective therapeutic strategies remain limited. This study elucidates the mechanism by which baicalin ameliorates CP progression through modulation of the interferon‐α/β receptor (IFNAR)/janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway. In a caerulein‐induced CP rat model, baicalin treatment (100 mg/kg/day, 6 weeks) markedly reduced pancreatic injury, collagen deposition, and α‐smooth muscle actin (α‐SMA) expression, alongside decreased serum levels of IL‐6, TNF‐α, TGF‐β, amylase, and lipase. Flow cytometry revealed that baicalin suppressed pancreatic infiltration of CD8 + T cells, macrophages, and NK cells while elevating regulatory T (Treg) cell proportions. Transcriptomic analysis identified JAK/STAT signaling as a key pathway inhibited by baicalin, with molecular docking confirming its direct binding to IFNAR. In vitro, baicalin (10 μM) attenuated TGF‐β1‐activated pancreatic stellate cell (PSC) activation, evidenced by reduced lipid droplet loss and α‐SMA/COL1A1 expression. Overexpression of IFNAR reversed baicalin's anti‐fibrotic effects, whereas co‐treatment with the JAK inhibitor ruxolitinib partially restored its efficacy. In vivo, IFNAR overexpression diminished baicalin's therapeutic benefits, but ruxolitinib co‐administration mitigated pancreatic damage. These findings demonstrate that baicalin alleviates CP fibrosis and islet dysfunction by targeting IFNAR to suppress JAK/STAT signaling, modulating immune cell dynamics, and inhibiting PSC activation. This study highlights IFNAR as a novel therapeutic target and positions baicalin as a promising candidate for CP treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Emergency Surgery Department, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
- Department of Graduate Studies, Bengbu Medical College, Bengbu, China.
- Department of Graduate Studies, Guangxi Medical University, Nanning, China.
ORCID-Profile: Chuanming Zheng
Förderung
- Key Natural Science Research Project of Anhui Provincial Department of Education
- General Program of Natural Science Foundation of Bengbu Medical University
- Scientific Research Project of Bengbu Medical College
Zitieren
APA
Dou, H., Tao, R., Yue, K., Cheng, F., Xu, Z., Wang, Z., & Zheng, C. (2025). Baicalin Alleviates Chronic Pancreatitis Fibrosis and Islet Dysfunction via Targeting IFNAR ‐Mediated JAK / STAT Signaling and Immune Modulation. The FASEB Journal. https://doi.org/10.1096/fj.202501649r
Vancouver
Dou H, Tao R, Yue K, Cheng F, Xu Z, Wang Z, et al. Baicalin Alleviates Chronic Pancreatitis Fibrosis and Islet Dysfunction via Targeting IFNAR ‐Mediated JAK / STAT Signaling and Immune Modulation. The FASEB Journal. 2025. doi:10.1096/fj.202501649r
BibTeX
@article{Dou2025,
author = {Dou, Hehe and Tao, Rui and Yue, Kan and Cheng, Feng and Xu, Zhipeng and Wang, Zhenjie and Zheng, Chuanming},
title = {Baicalin Alleviates Chronic Pancreatitis Fibrosis and Islet Dysfunction via Targeting IFNAR ‐Mediated JAK / STAT Signaling and Immune Modulation},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202501649r}
}
EUVIMED